Pathophysiology of Cancer Related Fatigue (CRF) and Chronic Fatigue (CFS/ME) by Lipidomics, Metabolomics, Microbiome and Exome Analysis and Investigation of Clinical Improvement Under Administration of Probiotics

What this Trial Is About

Researchers are studying the underlying causes of Cancer Related Fatigue (CRF) and Chronic Fatigue Syndrome (CFS/ME) by analyzing blood lipids, metabolites, genetic information, and gut bacteria in patients with and without fatigue. They compare findings from patients with tumor disease both with fatigue and without fatigue, as well as healthy individuals matched by age and gender. The study also explores the possible benefits of probiotics in improving fatigue symptoms. Participants are randomly assigned to receive either probiotics containing various beneficial bacteria strains or a placebo made of corn starch. These probiotics include several types of Bifidobacterium, Lactobacillus, and Streptococcus species. The study groups include patients with tumor disease who have or do not have fatigue, and healthy control groups. The trial is single-blinded and involves administration of the probiotic or placebo. During the study, researchers collect and analyze samples for lipidomics, metabolomics, exome, and microbiome changes. Participants undergoing abdominal surgery may have samples taken from the peritoneal microbiome. Fatigue symptoms are assessed, with the main outcome measure being improvement in fatigue three months after chemotherapy ends. The study includes follow-up assessments to monitor changes and safety, with total participation lasting several months.

Research for Pathophysiology of Cancer Related Fatigue (CRF) and Chronic Fatigue (CFS/ME)